Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Vivimed Labs's Debt-to-EBITDA or its related term are showing as below:
NSE:VIVIMEDLAB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -44.82 Med: 3.23 Max: 60.35
Current: -34.83
During the past 13 years, the highest Debt-to-EBITDA Ratio of Vivimed Labs was 60.35. The lowest was -44.82. And the median was 3.23.
NSE:VIVIMEDLAB's Debt-to-EBITDA is ranked worse than 100% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs NSE:VIVIMEDLAB: -34.83
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Vivimed Labs Debt-to-EBITDA Related Terms
Vivimed Labs Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Vivimed Labs's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VIVIMEDLAB vs ZTS, UTHR: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivimed Labs Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vivimed Labs's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Vivimed Labs (NSE:VIVIMEDLAB) has a Debt-to-EBITDA of 0.00 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vivimed Labs. According to the industry distribution chart, Vivimed Labs ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Vivimed Labs' Debt-to-EBITDA too high?
Vivimed Labs' current Debt-to-EBITDA is 0.00. Based on the distribution chart, Vivimed Labs ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vivimed Labs has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivimed Labs ranks #999999 out of 690 companies for Debt-to-EBITDA. This places Vivimed Labs in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vivimed Labs. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivimed Labs's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.54, compared to a current price of ₹5.23 — trading 105.9% above its estimated fair value. The current Debt-to-EBITDA is 0.00. Vivimed Labs' overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued.
The current stock price of ₹5.23 is trading 105.9% above its estimated GF Value™ of ₹2.54.
GuruFocus considers Vivimed Labs to be Significantly Overvalued.
Key valuation signals for NSE:VIVIMEDLAB:
Debt-to-EBITDA: 0.00
GF Value™: ₹2.54 vs. price of ₹5.23 (105.9% above fair value)
No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
42GF Score
Get the complete analysis for NSE:VIVIMEDLAB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VIVIMEDLAB has been successfully added to your 
